# Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

> **NCT00820742** · — · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Macugen

## Key facts

- **NCT ID:** NCT00820742
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-02
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820742, "Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00820742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*